Reply to comment on "Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis"
Clin Cardiol
.
2022 Jul;45(7):687-690.
doi: 10.1002/clc.23852.
Epub 2022 May 30.
Authors
Linggen Gao
1
,
Bin Wang
1
,
Rui Cheng
1
Affiliation
1
Department of Comprehensive Surgery, General Hospital of Chinese People's Liberation Army & National Clinical Research Center for Geriatric Disease, Beijing, China.
PMID:
35634754
PMCID:
PMC9286322
DOI:
10.1002/clc.23852
No abstract available
Publication types
Letter
Comment
MeSH terms
Allopurinol / adverse effects
Febuxostat* / adverse effects
Gout Suppressants / adverse effects
Gout* / drug therapy
Humans
Substances
Gout Suppressants
Febuxostat
Allopurinol